Debate On Antiplatelet Gene Testing Continues; First Point-Of-Care PMA Filed
Nanosphere submitted a PMA late last month for the first point-of-care assay that could make genotyping a more feasible routine tool to guide antiplatelet therapy
Nanosphere submitted a PMA late last month for the first point-of-care assay that could make genotyping a more feasible routine tool to guide antiplatelet therapy